MEGAVAC 7 Vaccine

Indications

• Acute respiratory infection
• Conjunctivitis
• Gastroenteritis
• Cystitis
• Meningitis
• Pneumonia

Dosage

Children: There is no specific dosage as adenovirus infections are generally self-limiting. Symptomatic treatment is advised.

Adults: There is no specific dosage as adenovirus infections are typically self-limiting. Supportive care is recommended.

Mechanism of action

Adenoviruses infect host cells through interactions with specific receptors on the cell surface, facilitating virus entry and subsequent release of viral DNA into the host cell nucleus. The viral DNA then utilizes the host cell's machinery to replicate and produce new viral particles, eventually leading to cell lysis and the release of new virions.

Pharmacodynamics

The clinical manifestations of adenovirus infections can range widely depending on the serotype and host factors. The immune response plays a critical role in controlling the infection, with both innate and adaptive immunity contributing to viral clearance. In general, adenovirus infections stimulate a robust immune response, which may cause symptoms such as fever, sore throat, and conjunctivitis.

Pharmacokinetics

Adenoviruses are typically transmitted via respiratory droplets or direct contact with contaminated surfaces. After exposure, the viruses can replicate in the epithelial cells of the respiratory tract, conjunctiva, or gastrointestinal tract. The viral shedding can occur for several days to weeks, depending on the individual's immune response. Adenoviruses do not have a specific treatment, and management focuses on symptomatic relief and supportive care.

Adverse effects

• Fever
• Sore throat
• Cough
• Conjunctivitis
• Diarrhea
• Pneumonia
• Bronchitis
• Sinusitis

Precautions

• In immunocompromised patients, adenovirus can cause severe disease.
• Caution should be exercised in individuals with underlying respiratory conditions.

Pregnancy

Adenovirus infections can occur during pregnancy, but specific risks to the fetus are not well established. Consultation with healthcare providers is advised.

Breast-feeding

Adenovirus can be transmitted through breast milk; however, the clinical significance is not clear. Breastfeeding mothers should consult healthcare professionals if they are infected.

Storage

Adenoviruses are laboratory-based entities and are typically stored in controlled environments within laboratory settings, rather than as commercially available drugs.

Indications

• Dyspepsia
• Peptic ulcer disease
• Gastroesophageal reflux disease (GERD)
• Heartburn
• Diarrhea
• Mucosal irritations

Dosage

Children: Refer to the BNF for Children for appropriate dosing guidelines.

Adults: Refer to the BNF for specific dosing recommendations based on the condition being treated.

Mechanism of action

Aluminum acts as an astringent, causing local shrinkage or constriction of body tissues through osmotic flow of fluids away from the area of application. This mechanism assists in reducing mucous secretions and managing conditions such as peptic ulcers and diarrhea. Additionally, it can help in drying and hardening of tissues when applied topically.

Pharmacodynamics

Aluminum-based antacids work by neutralizing gastric acid, leading to an increase in gastric pH. This action helps to alleviate symptoms associated with excess gastric acid, such as heartburn and discomfort. The astringent properties of aluminum also contribute to its therapeutic effects in managing mucosal irritations and secretions.

Pharmacokinetics

Aluminum is absorbed minimally when taken orally, with a bioavailability of about 0.1 to 0.5%. The majority of aluminum is excreted renally, and its half-life can be prolonged in individuals with renal impairment. Long-term use may lead to accumulation and potential toxicity, particularly impacting bone and neurological health.

Interactions

• aluminiumhydroxide+deferasirox: Severe (decreases exposure)
• aluminiumhydroxide+enteralfeeds: Unknown (increases risk of blocked enteral or nasogastric tubes)
• aluminiumhydroxide+roxadustat: Unknown (decreases exposure)

Pregnancy

Aluminum compounds are generally considered safe in pregnancy when used as directed. However, excessive exposure should be avoided.

Breast-feeding

Aluminum is excreted in breast milk; caution is advised when administered to nursing mothers.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• aluminium hydroxide suspension
• aluminium hydroxide tablets

Indications

• pH stabilization in laboratory experiments
• buffering during physiological studies
• preparation of samples for biochemical assays
• maintenance of pH in parenteral fluids

Dosage

Children: Refer to specific buffer formulations for detailed dosing guidance.

Adults: Refer to specific buffer formulations for detailed dosing guidance.

Mechanism of action

Buffers work by neutralizing added acids or bases through chemical reactions. For example, a buffer composed of acetic acid and sodium acetate can absorb excess hydrogen ions (from added acids) or donate hydrogen ions (to neutralize added bases), thus stabilizing the pH of the solution. This equilibrium is governed by the Henderson-Hasselbalch equation, which relates pH to the concentrations of the acidic and basic components of the buffer.

Pharmacodynamics

The pharmacodynamics of buffers involves their capacity to maintain pH levels within a target range, which is essential for various physiological processes. For instance, physiological buffers such as bicarbonate and phosphate play critical roles in maintaining the acid-base balance in the body, ensuring proper cellular function, enzyme activity, and metabolic processes.

Pharmacokinetics

The pharmacokinetics of buffer components depends on their specific chemical nature. Weak acids and bases used in buffers are typically absorbed and metabolized according to their molecular characteristics. For instance, bicarbonate can be reabsorbed in the kidneys and plays a significant role in systemic pH regulation. However, since buffer solutions are not typically absorbed in the same way as pharmaceutical drugs, their pharmacokinetic profiles are less relevant in a conventional sense.

Pregnancy

Buffering agents are generally considered safe during pregnancy; however, specific formulations should be evaluated for safety and efficacy.

Breast-feeding

Most buffering agents are considered safe during breastfeeding, but it is advisable to consult healthcare providers regarding specific formulations.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Follow specific storage instructions on the product label.

Indications

• Pain management
• Inflammation
• Infections
• Chronic diseases
• Allergic reactions

Dosage

Children: Dosage for paediatric canines (puppies) also varies widely depending on the specific medication, age, and weight of the puppy. Veterinary guidance is crucial for determining appropriate doses.

Adults: Dosage for adult canines varies based on the specific medication and condition being treated. It is essential to consult veterinary guidelines or a veterinarian for appropriate dosing.

Mechanism of action

The mechanism of action of canine medications varies widely depending on the specific drug class. For example, non-steroidal anti-inflammatory drugs (NSAIDs) inhibit cyclooxygenase enzymes (COX-1 and COX-2), reducing the production of prostaglandins that mediate inflammation and pain. Antibiotics may work by inhibiting bacterial cell wall synthesis or protein synthesis, while corticosteroids reduce inflammation by inhibiting immune response.

Pharmacodynamics

Pharmacodynamics in canines involves understanding how drugs affect the body, including their therapeutic effects and potential side effects. For example, NSAIDs provide analgesic and anti-inflammatory effects, while antibiotics target specific pathogens to eliminate infections. The response to drugs can vary based on factors such as breed, age, and overall health status.

Pharmacokinetics

Pharmacokinetics in canine patients encompasses the absorption, distribution, metabolism, and excretion of drugs. Canine physiology can influence these processes; for example, drugs may be absorbed more quickly in dogs due to differences in gastrointestinal pH and transit time. Metabolism often occurs in the liver, with variations based on breed and age affecting drug clearance. Excretion primarily takes place through the kidneys.

Pregnancy

Safety during pregnancy has not been established. Consult a veterinarian for guidance.

Breast-feeding

Safety during lactation has not been established. Consult a veterinarian for guidance.

Storage

Store in a cool, dry place, away from direct sunlight. Keep out of reach of children.

Indications

• Preparation of injectable medications
• Reconstitution of powdered medications
• Dilution of concentrated solutions for safe administration
• Facilitation of oral dosing for patients with difficulty swallowing

Dosage

Children: Refer to specific drug guidelines for appropriate dilution and administration.

Adults: Refer to specific drug guidelines for appropriate dilution and administration.

Mechanism of action

Diluents do not have a specific pharmacological mechanism of action as they are generally inert substances. Their primary role is to provide a suitable medium for the solubilization of active ingredients, thereby facilitating their administration and absorption. The action of the drug being diluted will depend on its own pharmacodynamics once it is reconstituted or diluted in the appropriate diluent.

Pharmacodynamics

Pharmacodynamics of diluents is not applicable as they do not exert therapeutic effects on their own. Instead, they serve as a medium that may affect the release and absorption of the active drug once administered. The pharmacodynamic properties of the final dosage form will depend on the active drug and its interaction with the body.

Pharmacokinetics

Like pharmacodynamics, the pharmacokinetics of diluents are not specifically defined. Diluents are typically absorbed or metabolized based on their chemical nature. For example, sterile water for injection is rapidly absorbed and distributed in the body, while saline may influence electrolyte balance. The pharmacokinetics of the active drug will primarily determine the overall therapeutic outcomes post-dilution.

Pregnancy

Generally considered safe when used appropriately; however, specific diluents may have individual safety profiles.

Breast-feeding

Generally considered safe when used appropriately; specific recommendations may vary based on the diluent used.

Storage

Store at room temperature, away from light and moisture. Follow specific storage instructions for each formulation.

Formulations

• Normal saline
• Dextrose solutions
• Ringer's lactate
• Sterile water for injection

Indications

• Prevention of canine distemper through vaccination
• Supportive treatment for infected dogs

Dosage

Children: No specific dosage available, refer to guidelines for vaccination schedules.

Adults: No specific dosage available, refer to guidelines for vaccination schedules.

Mechanism of action

Canine distemper virus primarily infects and replicates in lymphoid tissue, leading to immune suppression, and subsequently affects epithelial tissues in the respiratory, gastrointestinal, and nervous systems. The virus enters host cells via the signaling lymphocytic activation molecule (SLAM) receptor, which is expressed on immune cells, facilitating its spread throughout the body.

Pharmacodynamics

The immune response to CDV involves both humoral and cellular immunity. Vaccination induces an immune response that generates neutralizing antibodies, which prevent viral entry into host cells. Infected animals may develop severe immunosuppression, making them susceptible to secondary infections. The clinical manifestations depend on the severity of the infection and the host's immune response.

Pharmacokinetics

The pharmacokinetics of canine distemper virus are not typically described in terms of absorption, distribution, metabolism, and excretion like conventional drugs. Instead, the focus is on viral replication and the host immune response. The incubation period for distemper can vary but generally ranges from 1 to 2 weeks. The duration of the immune response post-vaccination can last for several years, depending on the type of vaccine used.

Pregnancy

No specific data available on the effects of distemper treatment in pregnant individuals, consult relevant guidelines.

Breast-feeding

No specific data available on the effects of distemper treatment during breastfeeding, consult relevant guidelines.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Clinical term 1
• Common term 1
• Clinical term 2
• Common term 2

Dosage

Children: Refer to the BNF for Children for specific paediatric dosing guidelines.

Adults: Refer to the BNF for specific adult dosing guidelines.

Mechanism of action

Dose acts by modulating the activity of specific neurotransmitter receptors and ion channels, influencing various physiological pathways. Its precise mechanism may involve interactions with G-protein coupled receptors, leading to downstream signaling effects that impact cellular responses.

Pharmacodynamics

Dose exhibits a range of effects depending on the dosage and target tissues. It is known to alter neurotransmitter release, affect ion conductance, and influence metabolic pathways, thereby contributing to its therapeutic efficacy and potential side effects.

Pharmacokinetics

Dose is generally absorbed following administration, with peak plasma concentrations occurring within a specified timeframe. Its distribution is influenced by tissue binding and permeability across cell membranes. The drug is metabolized primarily in the liver, with metabolites being excreted via renal and biliary routes. The half-life can vary based on individual patient factors, including age, liver function, and other concurrent medications.

Dosage

Children: Refer to specific guidelines for pediatric dosing; consult the BNF for Children for accurate dosage information.

Adults: Refer to specific guidelines for use; dosage may vary based on the context of use.

Mechanism of action

Hydroxide ions act primarily as bases, neutralizing acids to form water and salts. They participate in various biochemical pathways, including selenium metabolism and the degradation of reactive oxygen species. Hydroxide can influence enzyme activity and stability by altering the pH of the environment, thereby affecting metabolic reactions.

Pharmacodynamics

Hydroxide ions can impact biological processes by changing the local pH, which influences enzyme activity, ion transport, and the solubility of other compounds. Their ability to neutralize acids can help regulate physiological pH, contributing to homeostasis in living organisms.

Pharmacokinetics

As an inorganic ion, hydroxide does not undergo traditional pharmacokinetic processes like absorption, distribution, metabolism, or excretion. Instead, it is rapidly equilibrated in biological fluids and participates in acid-base reactions, having immediate effects on the local environment.

Pregnancy

There is limited information regarding the use of hydroxide during pregnancy. Consult a healthcare professional for advice.

Breast-feeding

Limited data is available on the excretion of hydroxide in breast milk. Consult a healthcare professional before use.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Leptospirosis
• Icterhaemorrhagiae infection
• Severe bacterial infections
• Acute febrile illness

Dosage

Children: Paediatric dosing for leptospirosis requires careful consideration of the child's weight and age, and should be guided by current clinical guidelines and expert recommendations.

Adults: Antibiotic treatment involves specific dosing based on the chosen agent, often guided by renal function and severity of the disease. Refer to specific guidelines for appropriate antibiotic choice and dosing.

Mechanism of action

Leptospirosis is primarily caused by Leptospira bacteria, which invade host tissues and evade the immune response. The bacteria can enter the bloodstream, leading to systemic infection. They produce various virulence factors that impair host immune response, allowing for persistent infection and tissue damage.

Pharmacodynamics

The pharmacodynamics of treatments for leptospirosis, such as antibiotics, involve the inhibition of bacterial cell wall synthesis, protein synthesis, or nucleic acid synthesis, which ultimately leads to bacterial cell death. The effectiveness of treatment is influenced by the stage of the disease and the severity of the infection.

Pharmacokinetics

The pharmacokinetics of antibiotics used to treat leptospirosis vary by drug. Generally, these drugs are absorbed from the gastrointestinal tract, distributed throughout body tissues, and excreted mainly via the kidneys. The half-life and clearance rates depend upon the specific antibiotic used and the patient's renal function.

Pregnancy

The safety of icterohaemorrhagiae during pregnancy has not been established. Caution is advised.

Breast-feeding

It is not known if icterohaemorrhagiae is excreted in human milk. Caution is recommended.

Storage

Store at room temperature, away from light and moisture. Keep out of reach of children.

Indications

• Leptospirosis
• Acute febrile illness
• Renal failure due to leptospirosis
• Severe liver dysfunction
• Hemorrhagic manifestations

Dosage

Adults: Refer to the BNF for appropriate antibiotic treatment regimens based on clinical severity and patient factors

Mechanism of action

Leptospira bacteria invade host tissues and can evade the immune response, leading to systemic infection. They are known to bind to host cells through specific receptors, facilitating their entry and subsequent multiplication. The immune response to the infection may result in an inflammatory response, contributing to tissue damage and the clinical manifestations of leptospirosis.

Pharmacodynamics

The pathophysiology of leptospirosis involves both the virulence factors of Leptospira and the host's immune response. The bacteria can induce a strong inflammatory response, leading to vasculitis and tissue damage. Organ dysfunction may occur due to the direct effects of the bacteria and the resultant immune-mediated injury. The severity of the disease can vary greatly depending on the serovar of Leptospira involved and the host's immune status.

Pharmacokinetics

Leptospira has no direct pharmacokinetics as it is a bacterium rather than a drug. However, the treatment of leptospirosis typically involves antibiotics. Common antibiotics used include doxycycline, penicillin, and ceftriaxone. The pharmacokinetics of these antibiotics vary; for example, doxycycline is well-absorbed orally and has a long half-life, allowing for once or twice daily dosing, while penicillin has a shorter half-life and requires more frequent dosing. The clearance of these drugs is influenced by renal function, which may be compromised in patients with severe leptospirosis.

Adverse effects

• Fever
• Headache
• Muscle pain
• Nausea
• Vomiting
• Jaundice
• Rash
• Meningitis
• Pulmonary hemorrhage
• Acute kidney injury

Precautions

• Monitor renal function in patients with existing kidney issues
• Use caution in immunocompromised patients
• Assess liver function prior to treatment

Pregnancy

The safety of leptospira treatment during pregnancy has not been established. Use only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

Not well studied in breastfeeding women. Caution is advised.

Storage

Store at room temperature, away from direct sunlight. Keep out of reach of children.

Indications

• Energy source in metabolic disorders
• Component in nutritional supplements
• Used in food and beverage applications

Dosage

Children: Refer to specific product guidelines or dietary recommendations for paediatric use.

Adults: Refer to specific product guidelines or dietary recommendations for adult use.

Mechanism of action

Maltose is metabolized by enzymes such as maltase, which hydrolyzes maltose into two glucose molecules. These glucose molecules are then utilized in glycolysis and other metabolic pathways to produce energy. Maltose also participates in various biological processes, including trehalose biosynthesis and starch degradation.

Pharmacodynamics

Maltose is rapidly broken down into glucose, leading to an increase in blood glucose levels. This can provide a quick source of energy, making it beneficial in situations where rapid glucose availability is needed, such as during exercise or in hypoglycemic conditions. The metabolism of maltose can influence glycogen storage and utilization.

Pharmacokinetics

Maltose is readily absorbed in the intestine after being hydrolyzed into glucose. The absorption occurs primarily in the small intestine, where glucose is transported via sodium-glucose transporters (SGLT). Once in the bloodstream, glucose is distributed to tissues for energy utilization or stored as glycogen in the liver and muscles. The half-life of maltose in the bloodstream is short, as it is quickly converted to glucose.

Pregnancy

Maltose is generally considered safe during pregnancy as it is a naturally occurring sugar. However, it should be consumed in moderation.

Breast-feeding

Maltose is not known to have any adverse effects during breastfeeding and can be considered safe.

Storage

Store in a cool, dry place, away from direct sunlight.

Formulations

• Oral solution
• Powder for reconstitution
• Tablets

Indications

• Hypertension
• Angina pectoris
• Migraine prophylaxis
• Tachyarrhythmias
• Heart failure

Dosage

Children: Refer to the BNF for Children for pediatric dosing recommendations, as these will depend on the specific indication and the patient's age and weight.

Adults: Refer to the BNF for specific dosing guidelines, as it may vary based on the condition being treated and individual patient factors.

Mechanism of action

Nadolol exerts its effects by blocking beta-1 and beta-2 adrenergic receptors in the heart and peripheral vasculature. By antagonizing these receptors, nadolol decreases heart rate, myocardial contractility, and conduction velocity through the atrioventricular node, which reduces cardiac workload and oxygen consumption. Additionally, blockade of beta-2 receptors can lead to peripheral vasoconstriction, but this effect is generally outweighed by the overall reduction in heart activity.

Pharmacodynamics

Nadolol reduces heart rate and myocardial oxygen demand by inhibiting the actions of catecholamines on the heart. The drug also has a long half-life, allowing for once-daily dosing. The antihypertensive effects are due to decreased cardiac output and a reduction in renin release from the kidneys, which leads to lower levels of angiotensin II and subsequently vasodilation.

Pharmacokinetics

Nadolol is well absorbed following oral administration, with peak plasma concentrations occurring within 1 to 4 hours. It has a long elimination half-life of approximately 20 to 24 hours, allowing for once-daily dosing. Nadolol is primarily excreted unchanged in the urine, with minimal hepatic metabolism, making it suitable for use in patients with liver dysfunction. The drug's pharmacokinetic profile can be affected by renal impairment, necessitating careful monitoring and potential dose adjustments.

Pregnancy

There are no well-controlled studies of nadl in pregnant women. Its use should be considered only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether nadl is excreted in human milk. Caution should be exercised when administering to a nursing woman.

Storage

Store at room temperature, away from moisture and light. Keep out of reach of children.

Indications

• Infectious diseases caused by bacteria
• Viral infections
• Fungal infections
• Parasitic infections

Dosage

Children: Refer to the BNF for Children for specific dosing information based on the organism type and age.

Adults: Refer to specific guidelines for antimicrobial therapy based on the organism type and infection site.

Mechanism of action

The mechanism of action of organisms varies widely depending on the type. For example, bacteria can reproduce rapidly and may produce toxins that interfere with host cellular functions. Viruses invade host cells and hijack cellular machinery to replicate. Fungi can disrupt cell membranes and evade the immune response. Each organism has unique pathways for infection, propagation, and interaction with host defenses.

Pharmacodynamics

Pharmacodynamics of organisms relates to their growth, replication, and the effects they have on the host. Pathogenic bacteria can elicit immune responses leading to inflammation. Viruses often induce cellular apoptosis or necrosis, while fungi can cause damage through their metabolic byproducts. The interaction between the organism and the host's immune system is crucial in determining the severity of the disease.

Pharmacokinetics

Pharmacokinetics of organisms is not applicable as they do not have a pharmacokinetic profile like drugs. Instead, their behavior in the host can be characterized by their replication rate, survival in various environments, and the ability to develop resistance to antimicrobial agents. The distribution of organisms in the body, their elimination through immune responses, and their potential to establish reservoirs or persistence in host tissues are critical.

Indications

• Croup (laryngotracheobronchitis)
• Bronchiolitis
• Pneumonia
• Upper respiratory tract infections

Mechanism of action

Parainfluenza viruses enter host cells and replicate by binding to specific receptors on the cell surface, mainly through the hemagglutinin-neuraminidase (HN) and fusion (F) proteins. Once inside the cell, the viral RNA is released and hijacks the host's cellular machinery to produce viral proteins and replicate the viral genome, leading to the assembly of new virions. This process ultimately results in cell lysis and the release of new viral particles, facilitating the spread of infection.

Pharmacodynamics

The immune response to parainfluenza infection involves both innate and adaptive mechanisms. The initial response includes the release of cytokines and activation of immune cells, such as macrophages and T cells. This immune response aims to control viral replication and clear the virus from the respiratory tract. Symptoms associated with parainfluenza infections, such as cough and difficulty breathing, are often a result of inflammation and airway obstruction due to the immune response.

Pharmacokinetics

As a virus, parainfluenza does not have pharmacokinetics in the traditional sense applied to drugs; however, the viral replication cycle is crucial for understanding its behavior in the human body. Following exposure, the incubation period typically ranges from 2 to 7 days. The virus can be shed from the respiratory tract for several days, with peak shedding occurring at the onset of symptoms. The immune system gradually controls the infection, leading to the resolution of symptoms.

Adverse effects

• Fever
• Rhinorrhea
• Cough
• Sore throat
• Wheezing
• Shortness of breath
• Lethargy
• Croup
• Pneumonia

Precautions

• Monitor respiratory status in patients with underlying respiratory conditions
• Use caution in immunocompromised patients

Pregnancy

There are no known specific risks to pregnant women, but caution is advised.

Breast-feeding

Generally considered safe, but consult a healthcare provider.

Storage

Store in a cool, dry place away from direct sunlight.

Indications

• Fifth disease (erythema infectiosum)
• Aplastic crisis in patients with hemolytic anemia
• Parvovirus B19 infection in immunocompromised patients

Dosage

Children: There are no specific pharmacological treatments for parvovirus infections; management is supportive. In children, parvovirus B19 infection typically resolves on its own, and symptomatic treatment is

Adults: There are no specific pharmacological treatments for parvovirus infections; management is supportive. Adults with parvovirus B19 infection are generally advised to rest and manage symptoms such as fever and pain.

Mechanism of action

Parvovirus B19 infects erythroid progenitor cells in the bone marrow, leading to lysis of these cells and a subsequent decrease in red blood cell production. The virus attaches to its receptor, globoside (also known as P antigen), which is present on the surface of erythroid progenitor cells. This binding facilitates viral entry and replication, disrupting normal erythropoiesis.

Pharmacodynamics

Parvovirus B19's primary effect is on the hematopoietic system, particularly impacting the production of red blood cells. In immunocompetent individuals, infection typically results in mild symptoms and self-limiting disease. However, in individuals with compromised immune systems or underlying hematological conditions, the virus can lead to severe anemia and other complications due to its effect on erythroid progenitors.

Pharmacokinetics

Parvovirus does not follow traditional pharmacokinetic principles as it is a virus rather than a pharmaceutical agent. Its replication occurs intracellularly, and it is spread via respiratory droplets or blood. The incubation period ranges from 4 to 14 days, and viremia can persist for weeks. The immune response is crucial for clearing the virus, with specific antibodies developing within a few weeks of infection.

Adverse effects

• Fever
• Malaise
• Rash
• Joint pain
• Anemia
• Lethargy

Precautions

• Immunocompromised patients may experience more severe symptoms.
• Pregnant women should be cautious due to potential risks to the fetus.

Pregnancy

Parvovirus B19 infection during pregnancy can lead to serious complications, including fetal anemia and hydrops fetalis.

Breast-feeding

There is no evidence to suggest that parvovirus B19 is transmitted through breast milk.

Storage

Parvovirus is a virus and does not require storage in a conventional sense; however, specimens should be handled according to biosafety guidelines.

Indications

• Severe infections caused by multidrug-resistant Gram-negative bacteria
• Urinary tract infections
• Pneumonia due to multidrug-resistant organisms
• Sepsis caused by susceptible organisms
• Topical treatment of infections

Dosage

Children: Refer to the BNF for Children for appropriate dosing recommendations based on age and weight.

Adults: Refer to specific guidelines for dosing based on the severity of the infection and renal function, as dosing may vary significantly.

Mechanism of action

Polymyxin exerts its antibacterial effect by binding to the lipid A component of lipopolysaccharides in the outer membrane of Gram-negative bacteria. This binding disrupts the bacterial cell membrane integrity, leading to cell lysis and death. Polymyxin also affects membrane permeability, which results in the leakage of essential cellular contents.

Pharmacodynamics

Polymyxin demonstrates concentration-dependent bactericidal activity, meaning that higher concentrations lead to a more significant reduction in bacterial counts. Its efficacy is influenced by the local environment, including pH and the presence of divalent cations. Resistance mechanisms include modifications of the lipid A structure, which reduce polymyxin binding.

Pharmacokinetics

Polymyxin is poorly absorbed from the gastrointestinal tract, thus it is usually administered parenterally for systemic infections. It has a variable volume of distribution and is known to accumulate in renal tissues. The elimination half-life is approximately 6 to 12 hours, with renal excretion being the primary route of elimination. Dose adjustments may be necessary in cases of renal impairment.

Adverse effects

• Nephrotoxicity
• Neurotoxicity
• Allergic reactions
• Respiratory distress
• Nausea
• Vomiting
• Diarrhea

Precautions

• Use with caution in patients with renal impairment
• Monitor renal function during treatment
• Avoid concurrent use with other nephrotoxic agents

Pregnancy

Polymyxin is classified as category C. Use in pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether polymyxin is excreted in human milk. Exercise caution when administering to breastfeeding mothers.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

• Polymyxin B sulfate injection
• Polymyxin E (colistin) injection
• Topical formulations containing polymyxin B

Indications

• Bacterial infections
• Viral infections
• Epidemiological studies
• Antibiotic resistance monitoring

Dosage

Children: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Adults: Refer to specific antimicrobial treatment guidelines based on the strain identified and the infection site.

Mechanism of action

The mechanism of action for a strain depends on the type of microorganism it represents. For pathogenic bacteria, the strain may produce toxins, evade the host's immune response, or possess resistance mechanisms that allow it to survive in the presence of antibiotics. For viruses, strains may exhibit mutations that alter their ability to infect host cells or evade antiviral therapies.

Pharmacodynamics

Pharmacodynamics in the context of strains involves the interaction between the strain and the host's immune system, as well as the effects of specific antimicrobial agents on the strain. These interactions can influence the efficacy of treatments and the development of resistance.

Pharmacokinetics

Pharmacokinetics is not directly applicable to strains themselves but rather to the drugs used to treat infections caused by specific strains. Factors such as absorption, distribution, metabolism, and excretion of antimicrobial agents can vary depending on the strain's characteristics and the site of infection.

Pregnancy

There is limited information on the safety of strain in pregnancy. It is advisable to consult healthcare professionals for guidance.

Breast-feeding

Safety during breastfeeding is not well established. It is recommended to seek medical advice before use.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Indications

• Influenza
• HIV/AIDS
• Hepatitis B and C
• Herpes simplex virus infections
• Cytomegalovirus infections
• COVID-19
• Respiratory syncytial virus infections

Dosage

Children: Refer to specific antiviral agents for dosing guidance.

Adults: Refer to specific antiviral agents for dosing guidance.

Mechanism of action

Viruses infect host cells by attaching to specific receptors on the cell surface. Once inside, they hijack the host cell's machinery to replicate their genetic material and produce viral proteins. New viral particles are assembled and released from the host cell, often destroying the cell in the process. The specific mechanism can vary depending on the virus type, including integration into the host genome in retroviruses or utilizing specific pathways for replication.

Pharmacodynamics

The pharmacodynamics of antiviral agents depend on the specific virus and the mechanism of action. Antiviral drugs may inhibit viral entry into host cells, block viral replication, or prevent the assembly of new virions. The effectiveness of antiviral therapy often relates to the stage of viral replication and the immune response of the host.

Pharmacokinetics

Pharmacokinetics of antiviral drugs varies widely based on the specific medication used. Generally, antiviral agents are absorbed through the gastrointestinal tract and distributed throughout the body. They may undergo hepatic metabolism and are often excreted through the kidneys. The half-life of these drugs can range from a few hours to several days, influencing dosing schedules.

Mechanism of action

Aluminum Acetate is an astringent. An astrignent is a chemical that tends to shrink or constrict body tissues, usually locally after topical medicinal application. The shrinkage or constriction is through osmotic flow of water (or other fluids) away from the area where the astringent was applied. Astringent medicines cause shrinkage of mucous membranes or exposed tissues and are often used internally to check discharge of blood serum or mucous secretions. This can happen with a sore throat, hemorrhages, diarrhea, or with peptic ulcers. Externally applied astringents, which cause mild coagulation of skin proteins, dry, harden, and protect the skin. Acne sufferers are often advised to use astringents if they have oily skin. Astringents also help heal stretch marks and other scars. Mild astringent solutions are used in the relief of such minor skin irritations as those resulting from superficial cuts, allergies, insect bites, or fungal infections such as athlete's foot. Excessive dietary aluminum has been proposed to be a factor contributing to several neurological disorders in humans. Six 8-week-old female Swiss Webster mice were fed for 10 wk purified diets containing 100 (control), 500 or 1000 ug aluminum/g diet. Brain and liver lipid peroxidation was determined by evaluating the production of 2-thiobarbituric acid reactive substances in brain and liver homogenates in the presence or absence of 50 uM ferrous iron. 2-Thiobarbituric acid reactive substances production in the absence of iron in brain homogenates from mice fed the 1000 ug/g diet was higher (30%) than that in the 100 ug/g control group (3.1 vs 2.4 nmol 2-thiobarbituric acid reactive substances/mg protein). The addition of ferrous iron increased 2-thiobarbituric acid reactive substances production in brain homogenates from all 3 dietary groups. The iron induced 2-thiobarbituric acid reactive substances production was 26% higher in the 1000 ug/g brain homogenates than in the 100 ug/g group (4.9 vs 3.9 nmol 2-thiobarbituric acid reactive substances/mg protein). Brain 2-thiobarbituric acid reactive substances production in the presence and absence of iron was similar between the 100 and 500 ug/g aluminum groups. 2-Thiobarbituric acid reactive substances production in liver homogenates measured either with or without iron was similar for the 3 groups. These results show that, in mice, dietary aluminum intoxication leads to increased brain 2-thiobarbituric acid reactive substance production, suggesting that enhanced lipid peroxidation may be one possible mechanism underlying the neurological damage associated with increased tissue aluminum. Evidence is presented indicating that dementias are associated with a relative insufficiency of magnesium in the brain. Such insufficiency may be attributable to low intake or retention of magnesium; high intake of a neurotoxic metal, such as aluminum, which inhibits activity of magnesium requiring enzymes; or impaired transport of magnesium and/or enhanced transport of the neurotoxic metal into brain tissue. It is proposed that Alzheimer's disease involves a defective transport process, characterized by both an abnormally high incorporation of aluminum and an abnormally low incorporation that an altered serum protein contributes to the progression of Alzheimer's disease by having a greater affinity for aluminum than for magnesium, in contrast to the normal protein, which binds magnesium better than aluminum. The altered protein crosses the blood-brain barrier more efficiently than the normal protein and competes with the normal protein in binding to brain neurons. Binding of the altered protein to the target neurons would both facilitate aluminum uptake and impede magnesium uptake. Evidence suggests that albumin is the serum protein that is altered. Aluminum is established as a neurotoxin, although the basis for its toxicity is unknown. It recently has been shown to alter the function of the blood-brain barrier, which regulates ex